Strafford will be offering a webinar/teleconference entitled "Inducement to Infringe in Hatch-Waxman Litigation:  Lessons from Bayer Schering v. Lupin and AstraZeneca v. Apotex for Pharma Patents" on July 12, 2012 from 1:00 – 2:30 pm (EDT).  Thomas L. Irving and David P. Frazier, Ph.D. of Finnegan Henderson Farabow Garrett & Dunner will provide guidance on claim and label language; to proactively coordinate patent, regulatory and clinical personnel; and to maintain consistency between claims and likely or actual label language throughout patent prosecution and label negotiation with the FDA.  The webinar will review the following questions:

• What can be learned from the AstraZeneca v. Apotex and the Bayer Schering v. Lupin decisions?
• What are the best approaches to maintain consistency between claims and likely or actual label language?
• What steps can be taken to maintain the coordination of patent, regulatory and clinical personnel throughout the patent prosecution and label negotiation with FDA?

An interactive Q&A session will follow the presentation.

The registration fee for the webinar is $297 ($362 for registration and CLE processing).  Those registering by June 22, 2012 will receive a $50 discount.  Those interested in registering for the webinar, can do so here.